| HOME >> BIOLOGY >> TECHNOLOGY |
- These funds will be used to rapidly implement the first phase of the
production capacity and productivity expansion in order to meet
strongly increasing customer demand-
- No more concerns about raising additional capital now-
- The Company has decided not to proceed with the private placement of
the previously announced convertible debentures at present market
conditions-
LAVAL, Quebec, Sept. 8 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced today that it has entered into a new financing arrangement with Desjardins Group, which will provide the Company with up to $8.5 million in financing. The Company expects the funds to used to improve productivity and increase production capacity in order to meet the currently rapidly growing demand for its products.
Of the financing, $3 million is earmarked to purchase customized equipment to optimize the extraction process and to increase productivity and production capacity with a target of reaching 120 000 kg of Neptune Krill Oil (NKO(R)) production per year, doubling current capacity. Another $3.5 million of the financing will be allocated to refinance the long term debt of the Company at a lower annual interest rate of 7.71%. This refinancing of long term debt will allow the Company to save more than 2.5% of its interest charge and improve next year's cash flow. Finally, a line of credit initially of $1 million, which can be increased to $2 million, has also been established. Investissement Quebec participated in this financing by guaranteeing up to 38% of the financing, excluding the line of credit. "Obtaining better financing conditions, particularly in the context of the current credit environment, constitutes a validation of our financial strength and of our business plan," commented Xavier Harland, Director of Finance.
"This expansion of our capacity is crucial to meeting actual a
'/>"/>
| SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |